Ozempic was designed for diabetes, not weight loss. Here's the nuance.

What's this video probably claiming?

Based on the caption, @amalinamary appears to be pushing back against the popular narrative that Ozempic is primarily a weight loss drug. The framing, "Oh No... Bukan itu la niat asal dia" (That wasn't its original intention), suggests the video is correcting a misconception by explaining that semaglutide was developed to treat type 2 diabetes, not to help people lose weight for cosmetic reasons. The mention of GLP-1 mimicry and blood sugar control points to a basic explainer about the drug's mechanism. The hashtag combination of diabetes and weightlossprogress suggests the creator is trying to bridge both audiences while making a point about the drug being misused or misunderstood. This is a reasonable premise. The video is likely doing more good than harm in terms of framing, but the details matter enormously when you're talking about a drug that carries real clinical weight.

What does the science actually show?

Semaglutide was first approved by the FDA in December 2017 for type 2 diabetes management under the brand name Ozempic, at doses up to 1 mg weekly. The SUSTAIN trial program across multiple studies confirmed it reduced HbA1c by roughly 1.5 percentage points and delivered meaningful cardiovascular risk reduction in the SUSTAIN-6 trial (Marso et al., 2016, NEJM). Weight loss was a secondary finding, not the primary endpoint. However, when researchers ran the STEP trials using a higher 2.4 mg weekly dose and rebranded the drug as Wegovy, average body weight reduction hit 14.9 percent over 68 weeks in adults without diabetes (Wilding et al., 2021, NEJM). So the science tells a more complex story than either extreme: yes, it was designed for diabetes, but the weight loss effect was substantial enough to earn a separate FDA approval entirely. The mechanism, GLP-1 receptor agonism slowing gastric emptying and reducing appetite, does not care about your original intentions.

Where does the social media noise diverge from clinical reality?

The problem with the "Ozempic is only for diabetics" correction is that it can swing too far in the opposite direction and leave viewers thinking non-diabetic use is inappropriate or off-label abuse. It is not. Wegovy, the 2.4 mg formulation, received FDA approval for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition, in June 2021. Using semaglutide for weight loss in eligible patients is not misuse. It is approved medicine. The more accurate concern is that Ozempic specifically is being prescribed off-label for weight loss in patients who may not have diabetes, which creates genuine supply shortages for people who need it for glycemic control. A 2023 analysis published in JAMA Internal Medicine found that off-label prescribing of GLP-1 agonists increased sharply between 2021 and 2023, straining availability. That is the real issue, not whether the drug "should" be used for weight.

What should you actually know?

If you are watching this video in Malaysia, where it appears to be targeted given the Malay-language caption, the regulatory context matters. Semaglutide is available in Malaysia but access, pricing, and approved indications may differ from the US or EU. Before anyone interprets this video as a green light to ask their doctor for Ozempic as a diet drug, a few facts deserve attention. First, the drug requires a legitimate clinical assessment, not a TikTok diagnosis. Second, side effects are real and dose-dependent: nausea affects roughly 44 percent of users in clinical trials, and rare but serious risks include pancreatitis and a theoretical thyroid tumor risk flagged in animal studies (the clinical significance in humans remains under investigation). Third, stopping the drug typically results in substantial weight regain, as shown in the STEP 4 withdrawal study (Rubino et al., 2021, JAMA). This is a long-term medical intervention, not a short-term fix, and any platform or creator who implies otherwise is doing their audience a disservice.